📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial (2019)

First Author: Gold J

Attributed to: A Programme for ALS Care in Europe (ALS-CarE) funded by ESRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1080/21678421.2019.1632899

PubMed Identifier: 31284774

Publication URI: http://europepmc.org/abstract/MED/31284774

Type: Journal Article/Review

Parent Publication: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Issue: 7-8

ISSN: 2167-8421